CN100535004C - 用作神经变性疾病诊断的铁调节蛋白-2 - Google Patents

用作神经变性疾病诊断的铁调节蛋白-2 Download PDF

Info

Publication number
CN100535004C
CN100535004C CNB018148549A CN01814854A CN100535004C CN 100535004 C CN100535004 C CN 100535004C CN B018148549 A CNB018148549 A CN B018148549A CN 01814854 A CN01814854 A CN 01814854A CN 100535004 C CN100535004 C CN 100535004C
Authority
CN
China
Prior art keywords
irp
gly
leu
protein
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018148549A
Other languages
English (en)
Chinese (zh)
Other versions
CN1556815A (zh
Inventor
W·M·克施
L·安顿
W·J·克林
D-K·康
R·L·勒温
T·A·洛瓦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
US Department of Health and Human Services
Original Assignee
Loma Linda University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University, US Department of Health and Human Services filed Critical Loma Linda University
Publication of CN1556815A publication Critical patent/CN1556815A/zh
Application granted granted Critical
Publication of CN100535004C publication Critical patent/CN100535004C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018148549A 2000-08-04 2001-08-06 用作神经变性疾病诊断的铁调节蛋白-2 Expired - Fee Related CN100535004C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22286300P 2000-08-04 2000-08-04
US60/222,863 2000-08-04

Publications (2)

Publication Number Publication Date
CN1556815A CN1556815A (zh) 2004-12-22
CN100535004C true CN100535004C (zh) 2009-09-02

Family

ID=22834032

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018148549A Expired - Fee Related CN100535004C (zh) 2000-08-04 2001-08-06 用作神经变性疾病诊断的铁调节蛋白-2

Country Status (9)

Country Link
US (4) US20020165349A1 (https=)
EP (1) EP1355933A2 (https=)
JP (1) JP2004506420A (https=)
CN (1) CN100535004C (https=)
AU (1) AU2001284742A1 (https=)
CA (1) CA2417310A1 (https=)
MX (1) MXPA03000937A (https=)
RU (1) RU2003105882A (https=)
WO (1) WO2002012284A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AU2003273242A1 (en) * 2002-08-27 2004-03-19 Xavier Golay (Nmi) Microvascular blood volume magnetic resonance imaging
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP2295426A1 (en) * 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP4653542B2 (ja) * 2005-04-06 2011-03-16 株式会社東芝 画像処理装置
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
JP5718247B2 (ja) * 2008-12-12 2015-05-13 ベックマン コールター， インコーポレイテッド 非結合体化フィコビリタンパク質を含む、マルチカラーフローサイトメトリー組成物
US8580230B2 (en) * 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
EP2253716A1 (en) * 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
EP2642289A1 (en) 2012-03-20 2013-09-25 Sensirion AG Portable electronic device
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US20180284141A1 (en) * 2015-04-02 2018-10-04 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
IT201700105483A1 (it) * 2017-09-21 2019-03-21 Braindtech S R L Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie
JP6737995B2 (ja) * 2018-11-29 2020-08-12 株式会社Ｒｅｓｖｏ 精神疾患発症危険状態の診断用バイオマーカー
CN114446392B (zh) * 2022-01-21 2024-01-30 华东理工大学 确认蛋白质与核酸适配体结合时的关键精氨基酸残基位点的方法
CN114457067B (zh) * 2022-02-10 2024-10-25 中国科学院天津工业生物技术研究所 一种低成本快速去除dna合成中错误的方法
CN117417999B (zh) * 2023-11-27 2025-07-25 河南省人民医院 一种与ireb2基因相关的snp分子标记及其应用

Also Published As

Publication number Publication date
EP1355933A2 (en) 2003-10-29
WO2002012284A2 (en) 2002-02-14
AU2001284742A1 (en) 2002-02-18
MXPA03000937A (es) 2004-08-02
CA2417310A1 (en) 2002-02-14
US20020165349A1 (en) 2002-11-07
US20100041060A1 (en) 2010-02-18
RU2003105882A (ru) 2005-01-20
CN1556815A (zh) 2004-12-22
US20050260669A1 (en) 2005-11-24
JP2004506420A (ja) 2004-03-04
US20080020393A1 (en) 2008-01-24
WO2002012284A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
CN100535004C (zh) 用作神经变性疾病诊断的铁调节蛋白-2
US20110275086A1 (en) Negative correlation between irp-2 and transferrin receptor expression as a diagnostic of alzheimer's disease
WO2000053758A2 (en) Compositions and methods for the treatment of immune related diseases
CA2349159A1 (en) Activity dependent neurotrophic factor iii (adnf iii)
WO2017018787A1 (en) Improved cell-permeable (icp) parkin recombinant protein and use thereof
US7070940B2 (en) Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
US6579679B1 (en) Method for examining central nervous system diseases and method for screening remedies
US5312734A (en) CDNA encoding a dopamine transporter
US20120142099A1 (en) Novel bak binding protein, dna encoding the protein, and methods of use thereof
AU737406B2 (en) Activity dependent neurotrophic factor III (ADNF III)
WO2000021985A2 (en) Genes encoding olfactory receptors and biallelic markers thereof
JP5180582B2 (ja) Ｃｏｒｌ２遺伝子を標的としたプルキンエ細胞識別方法
JP3930855B2 (ja) プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
AU2008202723A1 (en) Iron Regulating Protein-2 (IRP-2) as a Diagnostic For Neurodegenerative Disease
EP0644934A1 (en) SEQUENCE OF HUMAN DOPAMINE TRANSPORTER cDNA
WO1993024628A9 (en) SEQUENCE OF HUMAN DOPAMINE TRANSPORTER cDNA
JP2000037192A (ja) 中枢神経系疾患の検査方法および治療薬のスクリ―ニング方法
HK1143169A (en) Activity-dependent neurotrophic factor iii (adnf iii)
JPH0977792A (ja) Ｔｂｐと複合体を形成する蛋白質、その遺伝子及び抗体ならびにそれらを用いた癌の診断法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090902

Termination date: 20130806